Your browser doesn't support javascript.
loading
Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium.
Morra, Anna; Jung, Audrey Y; Behrens, Sabine; Keeman, Renske; Ahearn, Thomas U; Anton-Culver, Hoda; Arndt, Volker; Augustinsson, Annelie; Auvinen, Päivi K; Beane Freeman, Laura E; Becher, Heiko; Beckmann, Matthias W; Blomqvist, Carl; Bojesen, Stig E; Bolla, Manjeet K; Brenner, Hermann; Briceno, Ignacio; Brucker, Sara Y; Camp, Nicola J; Campa, Daniele; Canzian, Federico; Castelao, Jose E; Chanock, Stephen J; Choi, Ji-Yeob; Clarke, Christine L; Couch, Fergus J; Cox, Angela; Cross, Simon S; Czene, Kamila; Dörk, Thilo; Dunning, Alison M; Dwek, Miriam; Easton, Douglas F; Eccles, Diana M; Egan, Kathleen M; Evans, D Gareth; Fasching, Peter A; Flyger, Henrik; Gago-Dominguez, Manuela; Gapstur, Susan M; García-Sáenz, José A; Gaudet, Mia M; Giles, Graham G; Grip, Mervi; Guénel, Pascal; Haiman, Christopher A; Håkansson, Niclas; Hall, Per; Hamann, Ute; Han, Sileny N.
Afiliación
  • Morra A; Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Jung AY; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Behrens S; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Keeman R; Division of Molecular Pathology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Ahearn TU; National Cancer Institute, NIH, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland.
  • Anton-Culver H; Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, California.
  • Arndt V; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Augustinsson A; Clinical Sciences, Department of Cancer Epidemiology, Lund University, Lund, Sweden.
  • Auvinen PK; Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.
  • Beane Freeman LE; Oncology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • Becher H; Cancer Center, Department of Oncology, Kuopio University Hospital, Kuopio, Finland.
  • Beckmann MW; National Cancer Institute, NIH, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland.
  • Blomqvist C; Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Bojesen SE; Institute of Biometry and Clinical Epidemiology, Charité -Universitätsmedizin Berlin, Berlin, Germany.
  • Bolla MK; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Brenner H; Department of Oncology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Briceno I; Department of Oncology, Örebro University Hospital, Örebro, Sweden.
  • Brucker SY; Copenhagen University Hospital, Copenhagen General Population Study, Herlev and Gentofte Hospital, Herlev, Denmark.
  • Camp NJ; Copenhagen University Hospital, Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev, Denmark.
  • Campa D; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Canzian F; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Castelao JE; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Chanock SJ; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Choi JY; German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Clarke CL; Medical Faculty, Universidad de La Sabana, Bogota, Colombia.
  • Couch FJ; Department of Gynecology and Obstetrics, University of Tübingen, Tübingen, Germany.
  • Cox A; Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Cross SS; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Czene K; Department of Biology, University of Pisa, Pisa, Italy.
  • Dörk T; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Dunning AM; Oncology and Genetics Unit, Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Investigacion Sanitaria Galicia Sur (IISGS), Vigo, Spain.
  • Dwek M; National Cancer Institute, NIH, Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, Bethesda, Maryland.
  • Easton DF; Department of Biomedical Sciences, Seoul National University Graduate School, Seoul, Korea.
  • Eccles DM; Cancer Research Institute, Seoul National University, Seoul, Korea.
  • Evans DG; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • Fasching PA; Department of Oncology and Metabolism, Sheffield Institute for Nucleic Acids (SInFoNiA), University of Sheffield, Sheffield, United Kingdom.
  • Flyger H; Department of Neuroscience, Academic Unit of Pathology, University of Sheffield, Sheffield, United Kingdom.
  • Gago-Dominguez M; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Gapstur SM; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • García-Sáenz JA; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Gaudet MM; School of Life Sciences, University of Westminster, London, United Kingdom.
  • Giles GG; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Grip M; Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom.
  • Guénel P; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
  • Haiman CA; Division of Population Sciences, Moffitt Cancer Center & Research Institute, Tampa, Florida.
  • Håkansson N; Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.
  • Hall P; St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, Manchester, United Kingdom.
  • Hamann U; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Han SN; Division of Hematology and Oncology, Department of Medicine David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California.
Cancer Epidemiol Biomarkers Prev ; 30(4): 623-642, 2021 04.
Article en En | MEDLINE | ID: mdl-33500318
BACKGROUND: It is not known whether modifiable lifestyle factors that predict survival after invasive breast cancer differ by subtype. METHODS: We analyzed data for 121,435 women diagnosed with breast cancer from 67 studies in the Breast Cancer Association Consortium with 16,890 deaths (8,554 breast cancer specific) over 10 years. Cox regression was used to estimate associations between risk factors and 10-year all-cause mortality and breast cancer-specific mortality overall, by estrogen receptor (ER) status, and by intrinsic-like subtype. RESULTS: There was no evidence of heterogeneous associations between risk factors and mortality by subtype (P adj > 0.30). The strongest associations were between all-cause mortality and BMI ≥30 versus 18.5-25 kg/m2 [HR (95% confidence interval (CI), 1.19 (1.06-1.34)]; current versus never smoking [1.37 (1.27-1.47)], high versus low physical activity [0.43 (0.21-0.86)], age ≥30 years versus <20 years at first pregnancy [0.79 (0.72-0.86)]; >0-<5 years versus ≥10 years since last full-term birth [1.31 (1.11-1.55)]; ever versus never use of oral contraceptives [0.91 (0.87-0.96)]; ever versus never use of menopausal hormone therapy, including current estrogen-progestin therapy [0.61 (0.54-0.69)]. Similar associations with breast cancer mortality were weaker; for example, 1.11 (1.02-1.21) for current versus never smoking. CONCLUSIONS: We confirm associations between modifiable lifestyle factors and 10-year all-cause mortality. There was no strong evidence that associations differed by ER status or intrinsic-like subtype. IMPACT: Given the large dataset and lack of evidence that associations between modifiable risk factors and 10-year mortality differed by subtype, these associations could be cautiously used in prognostication models to inform patient-centered care.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Estilo de Vida Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Asunto de la revista: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Estilo de Vida Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Cancer Epidemiol Biomarkers Prev Asunto de la revista: BIOQUIMICA / EPIDEMIOLOGIA / NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Países Bajos